CD8A and neoplasm: Intravenous administration of the nanoformulation alongside intraperitoneal administration of PD‐1 checkpoint blockade resulted in impressive control of tumor growth, upregulation of inflammatory markers, and the increased presence of CD8+ T cells in a B16F10 model.